Skip to main content

Table 2 Bivariate analysis by management site

From: Clinical characteristics and mortality associated with COVID-19 at high altitude: a cohort of 5161 patients in Bogotá, Colombia

Variable Overall (n = 5161) Outpatient (n = 854) Inpatient (n = 2970) Emergency room (n = 114) ICU (n = 1223) p-value
Median (IQ) Median (IQ) Missing (n) Median (IQ) Missing (n) Median (IQ) Missing (n) Median (IQ) Missing (n)  
Demographic
 Age median (IQR) 66 (53–77) 47 (31–64.7) 0 68 (56–79) 0 81 (71–85.7) 0 69 (59–76) 0 < 0.01*
 Days of hospital stay (IQR) 8 (4–13) 1 (0–2) 0 7 (5–11) 0 6 (1–14) 0 15 (10–24) 0 < 0.01*
 Days of ICU (IQR) - - - - - - - 9 (4–15)   -
 Body mass index median (IQR) 26.34 (23.4–29.38) 25.7 (23.3–28.8) 2 26.15 (23.4–28.8) 0 23.7 (23–29.3) 1 27 (24.2–30.8) 0 < 0.01*
Sex
 Female 2340 (45.34%) 489 (20%) - 1370 (58%) - 42 (1.7%) - 439 (18%) - < 0.01*
 Male 2821 (54.65%) 365 (12%) - 1600 (56%) - 72 (2.5%) - 784 (27%) - < 0.01*
Comorbidities
 Hypertension 1171 (22.68%) 82 (7.0%) - 723 (61%) - 27 (2.3%) - 339 (28%) - < 0.01*
 HIV 9 (0.17%) 1 (11%) - 7 (77%) - 0 (0%) - 1 (11%) - -
 COPD 290 (5.61%) 21 (7.2%) - 179 (61%) - 14 (4.8%) - 76 (26%) - < 0.01*
 Diabetes types 1 and 2 256 (4.96%) 25 (0.04%) - 138 (0.2%) - 10 (0.01%) - 83 (0.1%) - < 0.01*
Laboratory values (IQR)
 Leukocyte blood count 7,985 (0.2–262.9) 6.72 (5.23–9.11) 387 7.74 (5.72–10.42) 33 8.31 (5.99–11.82) 17 9.18 (6.68–12.9) 2 < 0.01*
 Neutrophil-lymphocyte ratio 6,0303 (3,4258–10,7008) 3.84 (2.3–6.68) 387 5.54 (3.2–9.71) 35 9.1 (5.7–17.63) 17 8.52 (4.8–14.74) 3 < 0.01*
 Haematocrit 43.4 (39.2–47) 44.1 (41–47.3) 386 43.2 (39–46.8) 29 42.1 (36–45.7) 17 43.7 (39.2–47.4) 2 < 0.01*
 Haemoglobin 14.5 (13–15.8) 14.7 (13.7–15.9) 386 14.4 (12.9–15.7) 28 14.1 (11.6–15.3) 17 14.6 (13–15.9) 2 < 0.01*
 D-Dimer 950 (540–1802.25) 755 (430–1253) 518 914 (530–1703) 347 1506 (962.7–3420.2) 24 1078 (585–2071) 124 < 0.01*
 LDH 337 (255–445) 293 (217–361.75) 448 318 (246–406) 218 429 (283.5–580.5) 23 420 (311–554.5) 76 < 0.01*
 Ferritin 881 (478–1612.5) 825 (615–1680) 817 786 (400–1492) 2765 1415 (826.5–1690) 106 1162 (705–2027) 1146 < 0.04*
 Procalcitonin 0.31 (0.12–1.01) 0.2 (0.08–0.54) 794 0.17 (0.09–0.53) 2288 0.57 (0.21–3.95) 79 0.49 (0.19–1.7) 431 < 0.01*
Outcome
 Alive 3856 (74%) 854 (22%) - 2459 (63%) - 0 (0%) - 543 (14%) - < 0.01*
 Dead 1305 (25%) 0 (0%) - 511 (39%) - 114 (8.7%) - 680 (52%) - < 0.01*
Oxygenation indices (IQR)
 S/F ratio at admission 339.28 (310.71–423.80) 433.3 (357.4–447.6) 159 339.2 (321.4–414.2) 0 278 (138.5–335.7) 5 321.4 (188–371.4) 2 < 0.01*
 S/F ratio at 48 h 325 (254.28–341.52) 328.5 (293–328.5) 617 328.5 (314.2–346.4) 113 268.7 (170–325) 41 240.8 (156.6–325) 35 < 0.01*
 P/F ratio at admission 233,3854 (180,9524–274,6429) 256 (216.7–293.2) 488 243.3 (203.8–279.5) 192 175.5 (92–227.7) 20 188.9 (106.8–247.6) 11 < 0.01*
 S/F ratio at ICU admission - - - - - - - 168.5 (105.5–255.5) 73 -
 P/F ratio at ICU admission - - - - - - - 118.14 (81.5–171.4) 111 -
  1. ICU intensive care unit, COPD chronic obstructive pulmonary disease, HIV human immunodeficiency virus, LDH lactate dehydrogenase, S/F oxygen saturation to fraction inspired oxygen, P/F partial pressure of oxygen to fraction inspired oxygen
  2. *P-value refers to statistically significant result